151 related articles for article (PubMed ID: 9435927)
21. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA
Ann Oncol; 2008 Mar; 19(3):461-4. PubMed ID: 18006892
[TBL] [Abstract][Full Text] [Related]
22. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
23. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
25. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
Alshreef A; MacQuilkan K; Dawkins B; Riddin J; Ward S; Meads D; Taylor M; Dixon S; Culyer AJ; Ruiz F; Chalkidou K; Edoka I
Value Health Reg Issues; 2019 Sep; 19():65-74. PubMed ID: 31096179
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine plus docetaxel combination therapy.
Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; MartÃn M; McKendrick J; Miles D; Twelves C; Hornberger J
Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N
J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057
[TBL] [Abstract][Full Text] [Related]
31. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Hong WK
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
[TBL] [Abstract][Full Text] [Related]
32. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
33. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
35. [Docetaxel therapy against anthracycline resistant breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
37. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
38. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients resistant to paclitaxel therapy.
Valero V
Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of docetaxel for breast cancer.
Lwin Z; Leighl N
Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]